))
Episode 21: Antibiotic Resistance: How CARB-X Helps New Companies Get a Running Start
Fetch error
Hmmm there seems to be a problem fetching this series right now.
Last successful fetch was on February 27, 2024 04:28 (
What now? This series will be checked again in the next day. If you believe it should be working, please verify the publisher's feed link below is valid and includes actual episode links. You can contact support to request the feed be immediately fetched.
Manage episode 337444513 series 3381207
Contenu fourni par Gunnar Esiason. Tout le contenu du podcast, y compris les épisodes, les graphiques et les descriptions de podcast, est téléchargé et fourni directement par Gunnar Esiason ou son partenaire de plateforme de podcast. Si vous pensez que quelqu'un utilise votre œuvre protégée sans votre autorisation, vous pouvez suivre le processus décrit ici https://fr.player.fm/legal.
Kevin Outterson, the Executive Director of Boston-based CARB-X, a global non-profit partnership dedicated to accelerating antibacterial research to tackle the global rising threat of drug-resistant bacteria, joins the podcast to talk with Gunnar about the early-stage landscape for biotechnology companies developing novel antibiotics. Unlike the AMR ActionFund, CARB-X doesn't take equity positions in new companies, but rather provides grants and infrastructure support for companies moving through the drug development process. Gunnar and Kevin also talk about the PASTEUR and DISARM Acts as potential legislative fixes for the antibiotic marketplace. Kevin also points to an assumption that has long been made about generic drugs, which falls short for antibiotics and leaves them in a place that leaves them vulnerable to present market conditions.
To learn more about listener data and our privacy practices visit: https://www.audacyinc.com/privacy-policy
Learn more about your ad choices. Visit https://podcastchoices.com/adchoices
23 episodes
Partager
